All In MedTech

Device Trial Radar · NCT00928395

Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms

Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation

Last checked: Nov 20, 2026Latest source record: May 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Jan 2009

Primary completion

Sep 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Uroplasty, IncNot on our public-company list
Sponsor type
Industry
First posted
Jun 26, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a modified extension study to the SUmiT protocol UPC082008 (NCT00534521) to observe and evaluate long term therapy with PTNS on overactive bladder symptoms. Subjects must have completed the 12 weekly treatments of the original protocol, the 13 week follow up assessment, be randomized to the PTNS arm, and be considered a positive responder with moderate or marked improvement in the SUmiT Trial to be enrolled in this study. All consenting responders will continue with active PTNS therapy at an initially prescribed protocol for approximately 3 months followed by individualized symptom-based frequency of visits as determined by the subject along with their treating clinician, for up to a total of 33 months post initial 12-week therapy for a total of 3 years.

Conditions

  • Urinary Bladder, Overactive

Interventions

  • Urgent PCDevice

    The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Reporting "Moderately" or "Markedly" Improved on the Global Response Assessment (GRA) at 36 Months as Compared to BaselineTime frame: 36 months total

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Gregory L. Davis, M.D., FACOG, Inc.

    Chico, California

  • Greenwich Urological Associates, P.C.

    Greenwich, Connecticut

  • Specialists in Urology

    Naples, Florida

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.